Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Shares Sold by State Street Corp

State Street Corp decreased its holdings in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) by 0.9% in the 3rd quarter, Holdings Channel reports. The firm owned 932,931 shares of the company’s stock after selling 8,307 shares during the period. State Street Corp’s holdings in Nautilus Biotechnology were worth $2,659,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently bought and sold shares of the company. Dimensional Fund Advisors LP increased its stake in Nautilus Biotechnology by 19.8% in the second quarter. Dimensional Fund Advisors LP now owns 574,844 shares of the company’s stock valued at $1,345,000 after purchasing an additional 94,908 shares during the period. MetLife Investment Management LLC acquired a new position in Nautilus Biotechnology in the 3rd quarter valued at about $87,000. The Manufacturers Life Insurance Company purchased a new stake in Nautilus Biotechnology during the 3rd quarter valued at approximately $67,000. SG Americas Securities LLC purchased a new stake in Nautilus Biotechnology during the 3rd quarter valued at approximately $50,000. Finally, Renaissance Technologies LLC lifted its position in Nautilus Biotechnology by 11.2% during the 2nd quarter. Renaissance Technologies LLC now owns 140,100 shares of the company’s stock worth $328,000 after acquiring an additional 14,100 shares during the period. Institutional investors and hedge funds own 50.71% of the company’s stock.

Nautilus Biotechnology Stock Performance

NAUT stock opened at $1.68 on Wednesday. Nautilus Biotechnology, Inc. has a one year low of $1.61 and a one year high of $3.25. The company has a fifty day moving average of $2.27 and a 200-day moving average of $2.48. The stock has a market capitalization of $210.95 million, a PE ratio of -3.00 and a beta of 1.14.

Nautilus Biotechnology (NASDAQ:NAUT) last announced its quarterly earnings data on Tuesday, October 29th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.04. During the same quarter last year, the company posted ($0.13) earnings per share. Equities analysts forecast that Nautilus Biotechnology, Inc. will post -0.57 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, The Goldman Sachs Group lowered Nautilus Biotechnology from a “neutral” rating to a “sell” rating and dropped their target price for the company from $2.25 to $1.75 in a report on Thursday, December 5th.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.